Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT05005468 | A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.(CAMFA-L) | unknown | Phase 2 | 61 | Shanghai Chest HospitalOTHER | 1 | Aug 13, 2021 |
| clinicaltrials |
| NCT04846452 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04998474 | FRAME-001 Personalized Vaccine in NSCLC | unknown | Phase 2 | 15 | Frame Pharmaceuticals B.V.INDUSTRY | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04982549 | A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC | unknown | Phase 2 | 35 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04872634 | A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment(SNK_ASTER) | unknown | Phase 1 / Phase 2 | 24 | NKMAX Co., Ltd.INDUSTRY | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04970693 | A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression | unknown | Phase 2 | 64 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT04968002 | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03439215 | PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer(PFROST) | unknown | Phase 2 | 20 | Fondazione Ricerca TraslazionaleOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04965831 | Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2021 | clinicaltrials |
| NCT04952168 | Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC | unknown | Phase 2 | 26 | Yuan ChenOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04941417 | Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients | unknown | Phase 2 | 60 | Peking Union Medical CollegeOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04541251 | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | unknown | Phase 2 | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT03447678 | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.(PEOPLE) | unknown | Phase 2 | 65 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04905550 | Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC | unknown | Phase 2 | 50 | Chongqing University Cancer HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04828395 | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer(F&C) | unknown | Phase 2 | 65 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04874844 | JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety | unknown | Phase 2 / Phase 3 | 420 | Beijing Dongfang Biotech Co., Ltd.INDUSTRY | 0 | May 10, 2021 | clinicaltrials |
| NCT04304248 | Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer(NeoTAP01) | unknown | Phase 2 | 30 | Hao LongOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT04865705 | Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer | unknown | Phase 2 | 33 | West China HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04725448 | Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | unknown | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | unknown | Phase 1 / Phase 2 | 96 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2021 | clinicaltrials |
| NCT02927340 | A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions | unknown | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00643318 | CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer | unknown | Phase 2 | 40 | Accuray IncorporatedINDUSTRY | 2 | Mar 5, 2021 | clinicaltrials |
| NCT04762030 | Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study | unknown | Phase 2 | 39 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT04382300 | Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions | unknown | Phase 2 | 39 | Shanghai Chest HospitalOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03006575 | Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04706949 | Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment | unknown | Phase 2 | 26 | Fudan UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04636593 | A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC | unknown | Phase 2 | 43 | First People's Hospital of HangzhouOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04675008 | Central Nervous System(CNS) Efficacy of Dacomitinib | unknown | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03254004 | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | unknown | Phase 2 | 70 | Samsung Medical CenterOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT04641754 | A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer | unknown | Phase 2 | 176 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04619537 | A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04619563 | A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT02977169 | To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04612673 | A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC | unknown | Phase 2 | 33 | China Medical University, ChinaOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04613804 | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04102982 | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer(MWA in NSCLC) | unknown | Phase 2 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT04592666 | Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer(APPEAL) | unknown | Phase 2 | 226 | Fudan UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03048500 | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04553887 | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial(AUTUMN) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04560244 | A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04398940 | A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544644 | A Study of Combination Therapy in NSCLC | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04506242 | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 74 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 9, 2020 | clinicaltrials |
| NCT04524299 | Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC | unknown | Phase 2 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 16, 2021source: clinicaltrials